S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

$1.54
-0.08 (-4.92 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$1.51
Now: $1.55
$1.59
50-Day Range
$1.36
MA: $1.47
$1.69
52-Week Range
$1.30
Now: $1.55
$10.70
Volume199,602 shs
Average Volume266,307 shs
Market Capitalization$2.89 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.52
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.99 per share

Profitability

Miscellaneous

Employees9
Market Cap$2.89 million
Next Earnings Date3/26/2020 (Confirmed)
OptionableNot Optionable

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.


Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Auris Medical's stock reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd (NASDAQ:EARS) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Auris Medical.

Has Auris Medical been receiving favorable news coverage?

Media coverage about EARS stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Auris Medical earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Auris Medical.

Are investors shorting Auris Medical?

Auris Medical saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 46,800 shares, an increase of 97.5% from the December 15th total of 23,700 shares. Based on an average daily volume of 178,900 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.0% of the shares of the company are sold short. View Auris Medical's Current Options Chain.

Who are some of Auris Medical's key competitors?

What other stocks do shareholders of Auris Medical own?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:
  • Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
  • Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
  • Colleen A. DeVries, SVP of Cogency Global Inc.

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (1.18%).

Which institutional investors are buying Auris Medical stock?

EARS stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $1.55.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $2.89 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

What is Auris Medical's official website?

The official website for Auris Medical is http://www.aurismedical.com/.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]


MarketBeat Community Rating for Auris Medical (NASDAQ EARS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  374 (Vote Outperform)
Underperform Votes:  361 (Vote Underperform)
Total Votes:  735
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Initial Coin Offering (ICO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel